Varex Imaging
VREX
18.44
0.00
0.00%
Varex Imaging
US · VREX
#3431 by market cap
18.44
0.00
0.00%
Live - 5344 symbols - heartbeat 23s ago
· 2026-10-08 10:09
Pre-market
18.69
+1.36%
After-hours
18.44
0.00%
- Market cap
- 783.03M
- P/E (TTM)i
- 34.79
- P/Bi
- 1.58
- EPSi
- -1.70
- Div yieldi
- 0.00%
- 52W posi
- 98%
Reader sentiment
Are you bullish or bearish on VREX?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Fair
- Altman Z-Score is 2.20, in the 1.8-3.0 "grey zone".
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +4.14% YoY
Margins
- Gross margin
- 34.40%
- Operating margin
- 7.83%
- Net margin
- -8.32%
Key ratios & quality
- Enterprise valuei
- 999.83M
- Altman Z-Scorei
- 2.20
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 773.40M | 780.60M | 738.30M | 818.10M | 859.40M | 893.40M | 811.00M | 844.60M |
| Gross profit | 253.90M | 256.70M | 190.20M | 271.50M | 283.50M | 290.30M | 256.90M | 290.50M |
| Selling & admin expenses | 123.40M | 128.10M | 142.20M | 125.50M | 118.30M | 128.40M | 137.80M | 133.30M |
| Research & development | 83.00M | 78.10M | 78.90M | 71.90M | 77.00M | 84.80M | 87.00M | 91.10M |
| Operating profit | 47.50M | 50.50M | -30.90M | 74.10M | 88.20M | 77.10M | 32.10M | 66.10M |
| Pretax profit | 25.70M | 21.50M | -72.60M | 28.60M | 44.50M | 31.30M | 5.00M | -59.20M |
| Tax | -2.60M | 5.70M | -15.20M | 10.70M | 13.70M | -16.60M | 53.30M | 10.70M |
| Net profit | 28.30M | 15.80M | -57.40M | 17.90M | 30.80M | 47.90M | -48.30M | -69.90M |
| Basic EPS | 1 | 0 | -1 | 0 | 1 | 1 | -1 | -2 |
| Diluted EPS | 0.72 | 0.40 | -1.49 | 0.43 | 0.73 | 1.07 | -1.20 | -1.70 |
| Line item | 2025-04 | 2025-07 | 2025-10 | 2026-01 | 2026-04 | 2026-07 |
|---|---|---|---|---|---|---|
| Revenue | 212.90M | 203.00M | 228.90M | 209.60M | 216.00M | 210.50M |
| Gross profit | 76.70M | 67.50M | 77.80M | 69.80M | 72.60M | 76.70M |
| Selling & admin expenses | 32.60M | 32.90M | 34.00M | 32.70M | 36.00M | 30.60M |
| Research & development | 22.00M | 21.40M | 24.20M | 21.70M | 22.20M | 23.30M |
| Operating profit | 22.10M | 13.20M | 19.60M | 15.40M | 14.40M | 22.80M |
| Pretax profit | 10.80M | -86.60M | 14.10M | 3.80M | -6.40M | 16.20M |
| Tax | 3.70M | 2.50M | 1.90M | 1.40M | 1.60M | 300.00K |
| Net profit | 7.10M | -89.10M | 12.20M | 2.40M | -8.00M | 15.90M |
| Basic EPS | 0 | -2 | 0 | 0 | 0 | 0 |
| Diluted EPS | 0.17 | -2.15 | 0.29 | 0.05 | -0.19 | 0.37 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 458.10M | 438.40M | 522.00M | 554.20M | 609.90M | 658.30M | 649.90M | 641.80M |
| Cash & ST investments | 51.90M | 29.90M | 100.60M | 144.60M | 89.40M | 193.90M | 200.50M | 155.10M |
| Inventory | 235.10M | 248.20M | 271.90M | 224.80M | 303.20M | 277.50M | 264.80M | 299.40M |
| Total assets | 987.90M | 1.04B | 1.14B | 1.15B | 1.18B | 1.25B | 1.21B | 1.11B |
| Total current liabilities | 152.00M | 175.10M | 160.60M | 166.60M | 173.10M | 162.80M | 195.90M | 187.20M |
| Short-term debt | 25.00M | 30.70M | 8.60M | 9.00M | 6.10M | 5.30M | 50.30M | 5.90M |
| Long-term debt | 364.80M | 364.40M | 452.80M | 431.70M | 412.30M | 441.10M | 397.10M | 366.00M |
| Total liabilities | 548,500,000.00 | 580,200,000.00 | 673,700,000.00 | 651,000,000.00 | 637,700,000.00 | 668,600,000.00 | 670,400,000.00 | 620,800,000.00 |
| Total equity | 439.40M | 458.70M | 465.80M | 496.50M | 546.70M | 581.00M | 543.20M | 486.60M |
| Retained earnings | 62.40M | 74.40M | 16.10M | 33.50M | 63.80M | 118.10M | 64.40M | -5.90M |
| Line item | 2025-04 | 2025-07 | 2025-10 | 2026-01 | 2026-04 | 2026-07 |
|---|---|---|---|---|---|---|
| Total current assets | 683.80M | 619.50M | 641.80M | 633.60M | 625.60M | 633.10M |
| Cash & ST investments | 223.00M | 152.60M | 155.10M | 125.60M | 88.30M | 99.20M |
| Inventory | 284.70M | 298.70M | 299.40M | 328.00M | 346.70M | 346.70M |
| Total assets | 1.36B | 1.07B | 1.11B | 1.10B | 1.09B | 1.10B |
| Total current liabilities | 168.80M | 176.70M | 187.20M | 163.00M | 195.30M | 187.40M |
| Short-term debt | 5.30M | 5.40M | 5.90M | 6.00M | 23.30M | 22.70M |
| Long-term debt | 565.80M | 366.00M | 366.00M | 366.20M | 329.00M | 328.90M |
| Total liabilities | 793,700,000.00 | 603,900,000.00 | 620,800,000.00 | 607,200,000.00 | 601,300,000.00 | 589,500,000.00 |
| Total equity | 563.90M | 469.50M | 486.60M | 490.80M | 488.10M | 510.50M |
| Retained earnings | 77.00M | -18.10M | -5.90M | -3.60M | -11.70M | 4.00M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 85.30M | 71.90M | 13.20M | 92.60M | 16.90M | 108.40M | 47.30M | 41.70M |
| Depreciation & amortization | 42.20M | 39.20M | 39.50M | 37.30M | 33.60M | 33.20M | 31.10M | 27.20M |
| Free cash flow | 64.90M | 52.10M | -10.30M | 77.50M | -4.40M | 87.70M | 20.40M | 18.80M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 53.40M | 31.30M | 102.10M | 146.10M | 90.60M | 154.00M | 170.40M | 147.10M |
| Line item | 2025-04 | 2025-07 | 2025-10 | 2026-01 | 2026-04 | 2026-07 |
|---|---|---|---|---|---|---|
| Operating cash flow | 16.60M | 7.70M | 7.90M | -16.10M | -1.50M | 21.00M |
| Depreciation & amortization | 6.60M | 6.80M | 6.70M | 6.80M | 6.80M | 7.00M |
| Free cash flow | 9.80M | 1.40M | 2.30M | -26.80M | -7.70M | 12.00M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 332.20M | 138.50M | 147.10M | 121.70M | 87.70M | 101.10M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 6.83 | 3.56 | -12.92 | 3.72 | 5.96 | 8.75 | -8.65 | -13.95 |
| ROA %i | 2.71 | 1.53 | -5.32 | 1.52 | 2.60 | 3.96 | -3.87 | -6.05 |
| ROIC %i | 5.15 | 3.74 | -3.73 | 4.65 | 5.77 | 6.50 | -3.25 | -5.58 |
| 5-year avg ROE %i | 16.28 | 10.86 | 4.49 | 2.52 | 1.43 | 1.79 | -0.70 | -0.93 |
| EBIT margin %i | 6.13 | 5.46 | -5.58 | 8.64 | 9.41 | 6.49 | 3.92 | -3.14 |
| FCF / sales %i | 8.39 | 6.67 | -- | 9.47 | -- | 9.82 | 2.52 | 2.23 |
| Current ratioi | 3.01 | 2.50 | 3.25 | 3.33 | 3.52 | 4.04 | 3.32 | 3.43 |
| Quick ratioi | 1.35 | 0.98 | 1.40 | 1.80 | 1.52 | 2.20 | 1.83 | 1.67 |
| Debt / assetsi | 39.46 | 38.03 | 42.52 | 40.03 | 36.85 | 37.57 | 38.76 | 35.75 |
| LT debt / equityi | 85.59 | 81.91 | 105.36 | 93.19 | 80.67 | 81.77 | 79.40 | 82.52 |
| Interest coveragei | 2.18 | 2.02 | -1.31 | 1.68 | 2.22 | 2.17 | 1.19 | -0.81 |
| Revenue CAGR (3Y) %i | 6.95 | 7.97 | 1.88 | 1.89 | 3.26 | 6.56 | -0.29 | -0.58 |
| Net income CAGR (3Y) %i | -29.95 | -39.06 | -- | -14.15 | 25.04 | -- | -- | -- |
| FCF CAGR (3Y) %i | 8.44 | 4.77 | -- | 6.09 | -- | -- | -35.91 | -- |
| Line item | 2025-04 | 2025-07 | 2025-10 | 2026-01 | 2026-04 | 2026-07 |
|---|---|---|---|---|---|---|
| ROE %i | -7.46 | -25.57 | -13.95 | -13.31 | -16.15 | 4.64 |
| ROA %i | -3.22 | -11.39 | -6.05 | -5.57 | -6.76 | 2.03 |
| ROIC %i | -2.38 | -12.18 | -5.58 | -5.20 | -6.70 | 4.95 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 5.63 | -4.71 | -3.14 | -2.91 | -5.12 | 6.44 |
| FCF / sales %i | 4.63 | 4.43 | 2.23 | -- | -- | -- |
| Current ratioi | 4.05 | 3.51 | 3.43 | 3.89 | 3.20 | 3.38 |
| Quick ratioi | 2.18 | 1.64 | 1.67 | 1.67 | 1.21 | 1.30 |
| Debt / assetsi | 43.51 | 36.41 | 35.75 | 36.02 | 34.45 | 33.96 |
| LT debt / equityi | 106.49 | 84.65 | 82.52 | 81.67 | 74.23 | 70.66 |
| Interest coveragei | 1.55 | -1.21 | -0.81 | -0.75 | -1.41 | 1.99 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Medical is the largest reported line at 63.66% of revenue, across 2 reported segments.
- industrial follows at 36.34%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Medical63.66%
industrial36.34%
Quote time 2026-10-08 10:09:38 · For reference only, not investment advice and not tailored to your situation.